Vaccine for advanced liver, bile duct, or pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial is testing an investigational vaccine (YMN-136) for people with advanced liver, bile duct, or pancreatic cancer that has not responded to standard treatments or is not tolerated. The vaccine aims to help your immune system fight the cancer. It may be an option if standard treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced liver, bile duct, or pancreatic cancer that has progressed after standard treatment, or you can't tolerate standard treatment.
- Your tumor tests positive for the IMP3 marker.
- You have at least one measurable tumor (by standard imaging criteria).
- You are in good general health (ECOG score 0 or 1) and have adequate organ function.
- You must agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mRNA vaccine for people with advanced liver cancer that has returned or spread after other treatments. The vaccine aims to help your immune system fight the cancer more effectively.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This study tests a combination of freezing the tumor (cryoablation), an investigational immunotherapy (QL1706), and a targeted therapy pill (lenvatinib) for people with advanced bile duct cancer that has progressed after initial treatment. The goal is to see if this new combination can help control the cancer and improve outcomes.
This trial tests a new vaccine (YMN-136) for people with colorectal cancer that has spread to the liver and hasn't responded to at least three prior treatments. The goal is to see if the vaccine can help control the cancer.
This study tests a new therapeutic vaccine designed to help your immune system fight advanced solid cancers. You would receive vaccine injections alongside standard cancer care if your cancer has progressed despite previous treatments.
This study tests a new medication called YMN-A02 for people with advanced liver cancer that has not responded to standard targeted and immunotherapy treatments. The goal is to see if this new drug can help shrink tumors or slow the cancer's growth.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.